KOL Insight: Ovarian Cancer [2020]

Therapy Trends KOL Insight: Ovarian Cancer

PARP inhibitors are set to further disrupt frontline treatment but what factors will govern the decision between Lynparza and Zejula? Despite PIII trial setbacks, KOLs see potential value for PD-1/L1 in combination with PARP inhibitors or bevacizumab – but do any combinations stand out? And KOLs see an uncertain future for VBL's ofranergene obadenovec - why? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.

I want an edge. Let's talk

Key questions answered

As first-line use of AstraZeneca/Merck & Co.'s Lynparza and GSK's Zejula increases what is the future for Clovis' Rubraca?
Is there further potential for PARP inhibitors in recurrent disease settings?
In what settings might Abbvie's late-stage veliparib find market position in the well-served PARP inhibitor class?
Why do KOLs have mixed views about the potential for folate receptor inhibitors in ovarian cancer?
Why are KOLs uncertain that Sotio's dendritic cell vaccine DCVAC/OvCa will change treatment practice?

Examples of Therapies Covered

•

Lynparza

•

Zejula

•

Rubraca

•

Veliparib

•

Tecentriq

•

Tecentriq

•

Opdivo

•

DCVAC/OvCa

•

Ofranergene obadenovec

•

Anti-folate receptor ADCs

Partial List of Participating KOLs

Professor of Obstetrics & Gynaecology,
Division of Gynecologic Oncology, Hospital of the University of Pennsylvania, USA
Professor of Gynecologic Oncology,
University of Arizona College of Medicine, USA
Professor of Gynecologic Oncology and Associate Director of Clinical Trials,
Levine Cancer Institute, Atrium Health,
Professor of Medical Oncology in the UCL Cancer Institute and Director of Cancer Research UK and UCL Cancer Trials Centre,
Honorary Consultant in Medical Oncology UCL Hospitals, UK.
Professor of Gynaecologic Oncology and Director of a gynaecological cancer centre,
Germany.

Contact us for a full list of KOLs

We engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.

Our-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.

Our reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.

Continuous Monitoring Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.	Boardroom Ready Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.	Deep Dive Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.

Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name *
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID

Contact Us

KOL Insight: Ovarian Cancer [2020]

Browse by